Comprehensive reviews of the literature related to management and diagnosis of pheochromocytoma are available elsewhere.
In view of the array of symptoms, the patient was referred for medical evaluation of a suspected pheochromocytoma, a neuroendocrine tumor of the adrenal gland. He underwent 24-hour blood pressure ...
Grossrubatscher and colleagues, therefore, evaluated the diagnostic value of chromogranin ... A in the assessment of surgical cure of pheochromocytoma was also investigated. The authors observed ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
adrenal incidentalomas have become an important clinical entity for which pheochromocytoma must be considered, regardless of signs and symptoms. Third, knowledge of the relationship between ...
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback